Balipodect is primarily investigated for its potential therapeutic applications in the treatment of psychiatric disorders, particularly schizophrenia. It functions as a phosphodiesterase 10A (PDE10A) inhibitor, which plays a role in regulating brain signaling pathways. By inhibiting PDE10A, it may help modulate dopamine and glutamate neurotransmission, addressing cognitive and behavioral symptoms associated with schizophrenia. Clinical studies are ongoing to evaluate its efficacy and safety as a novel treatment option for mental health conditions.